Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
3,45 SEK | -2,54% |
|
-4,83% | -13,97% |
13/06 | Transcript : Saniona AB - Special Call | |
29/05 | Saniona AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 | CI |
Attività
Numero di dipendenti: 23
Vendite per attività
SEK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 15 | 100,0 % | 17 | 100,0 % | +10,19% |
Vendite per regione
SEK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Germany
51,8
%
| - | - | 9 | 51,8 % | - |
United Kingdom
44,5
%
| - | - | 7 | 44,5 % | - |
Denmark
3,8
%
| - | - | 1 | 3,8 % | - |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | 66 | 01/01/11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01/01/11 |
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01/01/14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01/05/20 | |
Corporate Officer/Principal | 52 | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Director/Board Member | 66 | 01/01/15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19/01/18 |
Director/Board Member | 58 | 01/01/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 111 238 252 | 80 671 393 ( 72,52 %) | 0 | 72,52 % |
Coordinate società
![Indirizzo SANA AB(SANION)](https://cdn.zonebourse.com/static/address/55820157.png)
Società del gruppo
Nome | Categoria e settore |
---|---|
Saniona A/S
![]() Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Settore
Vendite per regione
Utili annuali - Indice di sorpresa
Variaz. 1 gen. | Capi. | |
---|---|---|
-13,97% | 37,07 Mln | |
+15,58% | 122 Mrd | |
+16,60% | 113 Mrd | |
+17,55% | 26,22 Mrd | |
-24,33% | 19,01 Mrd | |
-19,14% | 15,71 Mrd | |
-17,95% | 15,22 Mrd | |
-46,81% | 14,72 Mrd | |
+58,78% | 14,58 Mrd | |
+4,91% | 13,84 Mrd |
- Borsa valori
- Azioni
- Azione SANION
- Società SANA AB